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Established as a national resource for the production of diphtheria antitoxin, the SSI was from its inception concerned to deliver a quality product at a minimum price, and to link pharmaceutical production with research into, and further development of, biological products. In the course of the twentieth century, the institute acquired an international reputation for the quality of its products and its cutting edge research, and, in the 1920s, achieved international authority as the League of Nations Health Commission's central laboratory for the preservation and distribution of all standard sera and bacterial products.
2 The rise of the SSI to international prominence came about through a combination of factors, personal, scientific and political, but above all, perhaps, from its early association with questions of quality in the production of the new generation biological medicines, of which diphtheria antitoxin was the first to emerge.
Diphtheria and the development of the Danish State Serum Institute
The creation of the SSI was largely due to the energy and determination of Carl Julius Salomonsen (1847 Salomonsen ( -1924 , the 'father of danish bacteriology', 3 for Danish medical culture at that period was largely traditional with a focus on hospital medicine and general practice, rather than on research, let alone bacteriology.
4 Late nineteenth-century Denmark was a small state on the European periphery, with a population of just over two million in 1890, which was then beginning to adopt progressive social welfare policies in emulation of the German welfare model elaborated from the mid-1880s -a political Like almost every European state at this period, the country suffered severely from epidemic diphtheria in the years between c. 1880 and 1895; at the peak in 1893 a total of 23,695 cases were noted.
6 Public concern over the domestic tragedies resulting from this epidemic was considerable, and was not helped by press publicity. In 1890, for example, one of the leading Danish newspapers carried an article which graphically described the diphtheria wards at Copenhagen's isolation hospital where 'tragic children struggle against powerful death'. The article concluded: 7 We understand mothers' terror of this dreadful disease, that sometimes kills at once, sometimes when the child is convalescent. Diphtheria is nearly always followed by paralysis in the throat or the heart. When one believes a little child has recovered, it is suddenly overtaken by a heart attack, and tumbles over on the floor in its play, dead. (Author's translation)
In this context, Emile Roux's announcement in the summer of 1894 of the successful diphtheria antitoxin trials generated, as elsewhere, significant interest from a wide section of the general public as well as within the small medical community.
The significant mortalities and vivid popular anxieties which still surrounded several major infectious diseases in the 1880s generated perilous hopes of the new knowledge and new techniques that were beginning to emerge from the bacteriological laboratories. Although, as Jonathan Simon notes in his contribution to this volume, Roux was surprised by the avid public interest in the new anti-diphtheria serum in 1894, his reaction seems odd, even naïve. Given the intense popular anxieties that surrounded the disease, such a reaction seems predictable -more especially since precisely such an overwhelming public response had greeted Robert Koch's announcement of an apparent cure for tuberculosis in 1890. 8 The new therapies quickly altered public expectations and popular practices; the introduction of serum therapy and laboratory diagnosis, for example, reconciled the middle classes to hospital treatment for their sick offspring.
9 On the one hand anxiety generated popular interest and support for these new treatments, but on the other the treatments could also generate new concerns. Deaths associated with the new treatments, such as that of Ernst Langerhans described by Axel Hüntelmann, indicated that these novel therapies were not without risks, and could not be accepted as an unconditional good.
10
The introduction of these new therapies was in fact far from straightforward. Public acclaim and public suspicion, scientific rivalry, financial considerations and ethical issues surrounded their introduction into clinical practice. In the last two decades of the nineteenth century, the scientists who pioneered these techniques learned, faute de mieux, to negotiate conflicting
